Two Sectors, Two Playbooks
Technology and healthcare consistently produce the most IPOs by both volume and total capital raised. In 2025, they accounted for 62% of all U.S. IPO proceeds. Yet the investment thesis, valuation framework, and risk profile for each sector could not be more different.
Understanding these differences is essential for building a diversified IPO portfolio and knowing which opportunities match your risk tolerance and investment horizon.
The Tech IPO Landscape in 2026
Current Pipeline
The 2026 tech IPO pipeline is the strongest since 2021. A backlog of mature private companies — many of which delayed IPOs during the 2022–2023 rate-hiking cycle — are now ready to list. Key themes driving the pipeline:
AI Infrastructure. Companies building the picks-and-shovels of the AI boom: GPU cloud providers, data labeling platforms, vector database companies, and AI observability tools.
Vertical AI Applications. AI-native companies targeting specific industries: legal AI, healthcare AI, financial AI, and enterprise AI assistants that have moved beyond hype into real revenue.
Cybersecurity. Persistent demand driven by escalating threat landscape and regulatory requirements (SEC cybersecurity disclosure rules, EU NIS2 directive).
FinTech 2.0. A resurgence of fintech IPOs, this time with proven unit economics and regulatory clarity — embedded finance, B2B payments, and AI-powered underwriting.
Typical Tech IPO Profile
| Metric | Typical Range |
|---|---|
| Revenue at IPO | $200M–$800M ARR |
| Revenue Growth | 25–60% YoY |
| Gross Margin | 65–85% |
| Net Income | Usually negative (investing in growth) |
| Valuation Multiple | 8–20x forward revenue |
| Lock-up Period | 180 days standard |
What Drives Tech IPO Valuations
Revenue growth rate is king. A tech company growing at 50%+ can command 15–20x revenue even while unprofitable. The logic: high-margin software revenue is predictable and scalable. Investors are buying future profitability.
Other key drivers:
Post-IPO Performance Patterns
Tech IPOs tend to show strong first-day pops (median 15–25%) followed by volatile trading. The six-month post-IPO period is critical:
The Healthcare IPO Landscape in 2026
Current Pipeline
Healthcare IPOs in 2026 span three distinct sub-sectors, each with fundamentally different economics:
Biotech / Biopharma. Companies developing novel therapeutics. These are binary-outcome investments: the drug either works or it does not. The pipeline is rich in oncology, rare disease, GLP-1 analogs, and gene therapy candidates.
Medical Devices. Companies with FDA-cleared (or approaching clearance) medical devices. These tend to have more predictable revenue paths than biotech but lower valuation multiples.
Health Tech. Software companies serving healthcare — electronic health records, telehealth, clinical trial management, and AI diagnostics. These increasingly resemble tech IPOs in their financial profiles.
Typical Biotech IPO Profile
| Metric | Typical Range |
|---|---|
| Revenue at IPO | $0–$50M (often pre-revenue) |
| Cash Runway | 18–30 months post-IPO |
| Lead Program Phase | Phase 2 or Phase 3 |
| Valuation | Based on pipeline potential, not revenue |
| Lock-up Period | 180 days standard |
Typical MedTech / HealthTech IPO Profile
| Metric | Typical Range |
|---|---|
| Revenue at IPO | $50M–$300M |
| Revenue Growth | 15–35% YoY |
| Gross Margin | 55–75% |
| Valuation Multiple | 5–12x forward revenue |
| Lock-up Period | 180 days standard |
What Drives Healthcare IPO Valuations
For biotech, valuation is driven by the risk-adjusted net present value (rNPV) of the drug pipeline. Key factors:
For medtech and health tech, valuation follows a more traditional revenue-multiple model, similar to tech but at lower multiples due to healthcare's regulatory complexity and slower sales cycles.
Head-to-Head Comparison
Valuation Multiples
Tech IPOs consistently command higher revenue multiples than healthcare:
The premium reflects software's inherent scalability — zero marginal cost per customer — versus healthcare's regulatory, reimbursement, and clinical complexity.
Time to Profitability
Tech: High-growth tech companies typically reach profitability within 2–4 years post-IPO if they choose to. Many defer profitability to maximize growth, but the path is visible and controllable.
Healthcare: Biotech companies may take 5–10 years (or never) to reach profitability, depending on clinical trial outcomes and commercialization success. MedTech companies are typically closer to profitability at IPO.
Risk Profiles
Tech risks: Primarily competitive and execution-related. A tech company with product-market fit faces risks from new entrants, platform shifts, and economic cycles — but these risks are manageable and diversifiable.
Healthcare risks: Binary regulatory outcomes. An FDA rejection or failed Phase 3 trial can destroy 50–80% of a biotech company's value overnight. This risk is unhedgeable and specific to individual companies.
Regulatory Burden
Tech: Relatively light regulatory oversight (though increasing for AI, data privacy, and antitrust). Companies can iterate quickly and launch products without government approval.
Healthcare: Intense regulatory scrutiny at every stage. FDA approval processes take years and cost hundreds of millions. Post-approval surveillance, manufacturing quality, and reimbursement negotiations add further complexity.
Investment Strategies by Sector
Tech IPO Strategy
For growth investors: Focus on companies with >40% revenue growth, >120% net dollar retention, and clear category leadership. Accept higher multiples for superior growth.
For value investors: Wait for the post-IPO correction. Many tech IPOs overshoot on day one and settle 20–30% lower within six months. The lock-up expiration (day 180) often creates the best entry point.
Portfolio allocation: Tech IPOs suit investors comfortable with volatility who have a 3–5 year horizon. They work well as growth allocations within a diversified portfolio.
Healthcare IPO Strategy
For biotech specialists: Invest based on clinical data, pipeline diversity, and management track record. Understand the science or rely on expert analysis. Consider spreading capital across multiple biotech IPOs since individual outcomes are binary.
For risk-averse healthcare exposure: Prefer medtech and health tech IPOs, which offer healthcare exposure with more predictable revenue and lower binary risk.
Portfolio allocation: Biotech IPOs are high-risk/high-reward and should represent a smaller portfolio allocation. MedTech and health tech can be core holdings.
What 2026 Pipeline Data Tells Us
Based on current S-1 filings and known IPO preparations:
Tech pipeline strength: Very strong. AI tailwinds, normalized interest rates, and a backlog of mature private companies create favorable conditions. Expect 40–60 tech IPOs raising $30B+ in total.
Healthcare pipeline: Moderate. Biotech remains active in oncology and rare disease, but the bar for clinical data quality has risen. MedTech and health tech are steady contributors. Expect 25–40 healthcare IPOs raising $15–20B.
Cross-sector trend: AI-powered healthcare companies blur the line between tech and healthcare. Companies applying AI to drug discovery, diagnostics, or clinical operations may be classified as either sector — and they often command tech-like multiples for healthcare domain expertise.
Conclusion
Tech and healthcare IPOs require fundamentally different analytical frameworks. Tech investors should focus on revenue growth, retention, and competitive moats. Healthcare investors must understand regulatory pathways, clinical data, and pipeline risk.
The most sophisticated IPO investors allocate across both sectors, using tech for growth and healthcare for asymmetric upside. AI-powered tools like IPO.AI can help analyze both types of S-1 filings, benchmark valuations, and identify opportunities that match your investment thesis.
The 2026 IPO market offers compelling opportunities in both sectors — the key is knowing which lens to apply.